Table of Contents
Introduction:
company that operates tissue-level therapeutic pharmaceuticals for the treatment of patients’ degenerative disorders. The business identifies novel biological functions and targets in the Wnt pathway, enabling the creation of small molecule therapeutics with the potential to treat a wide range of cancers and degenerative diseases. Biosplice Therapeutics.
A clinical-stage biotechnology business called Biosplice Therapies is leading the development of novel therapeutics for serious diseases based on alternative pre-mRNA splicing. Its scientific foundation is based on biological findings that control tissue specialisation and allow it to use tiny chemicals to specifically remove damaging proteins.
Through the selective reprogramming of cellular behaviour, the company’s focus is on the realisation of new, potentially curative therapies for patients. This includes the company’s fundamental discoveries in Wnt pathway modulation as well as unlocking the broad therapeutic potential of the CLK/DYRK target class.
About:
Private biopharmaceutical business Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is situated in San Diego, California. Osman Kibar created it in 2008. Products under development by Samumed aim to block novel Wnt signalling pathway components. The business’s osteoarthritis programme is the most sophisticated and focuses exploring potential remedies for a variety of ailments.
A new biotechnology investment syndicate has provided $120 million in equity funding to Biosplice Treatments, Inc. (“Biosplice”), a clinical-stage biotechnology firm that is developing novel therapeutics based on alternative pre-mRNA splicing for serious disorders.
Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and other investors participated in this most recent round, which also included previous investor backing. In connection with the funding, the company’s board of directors will welcome Joy Ghosh, PhD, of Eventide Asset Management, and Gur Roshwalb, MD, of aMoon.
Based on the cutting-edge science of alternative pre-mRNA splicing, Biosplice is creating first-in-class small-molecule therapies. A novel biological mechanism connecting CLK/DYRK kinases to the therapeutic regulation of alternative splicing has been revealed by Biosplice, building on fundamental discoveries in the modulation of the Wnt pathway.
An fundamental biological mechanism called alternative splicing controls the diversity of proteins in cells, which in turn affects the kind and function of the cell. Tissue-specific mRNA splice sites are chosen by Biosplice’s target class, which makes them desirable, druggable targets within the cellular “command and control” centre.
Lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for several malignancies, and a wide pipeline covering anything from Alzheimer’s disease to various degenerative disorders are among the medications being developed by Biosplice.
Website : https://www.biosplice.com/default.aspx
Founder & Team:
The private biopharmaceutical company Biosplice Therapeutics, formerly known as Samumed, was founded by Osman Kibar. 2008 saw its founding. The headquarters of Biosplice Therapeutics are in San Diego, California, in the US.
History:
There is no historical data.
Biosplice Therapeutics Highlight:
| Company Name | Biosplice Therapeutics |
| Founders | Osman Kibar |
| Started at | 2008 |
| Competitors | Twist Bioscience, Lycia Therapeutics, And Seismic Therapeutic |
| Website | https://www.biosplice.com |
| Revenue | – |
| Country | USA |
| Customer care Email | – |
| Customer care Contact details | – |
| Company Valuation | $11.6 billion |
| Industry | Pharmacutecal/ Biotech |
| Headquarters | San Diego, California, United States |
Revenue:
There is no data of it.
Funding & Investors:
Biosplice is a San Diego, California-based company that is creating small-molecule therapies based on the cutting-edge field of alternative pre-mRNA splicing. The most recent fundraising round for Biosplice Therapeutics was a Series B for $120M on April 15, 2021. In August 2018, Biosplice Therapeutics was valued at $12,000M.
| DATE | INVESTORS | AMOUNT | ROUND |
| – | Swicorp | N/A | – |
| Not yet verified | |||
| Sep-12 | Esas Ventures | N/A | Seed |
| Sep-13 | Vickers Venture Partners | $220m | Series A |
| Polar Light Ventures | |||
| Starling group | |||
| Aug 2018* | Vickers Venture Partners | $438m | Series B |
| Starling group | Valuation: $11.6b | ||
| Apr-19 | Christian Cadeo | N/A | Series C |
| Cem Ortabaş | |||
| Apr-21 | Sands Capital | $120m | Late VC |
| aMoon Fund | Valuation: $11.6b | ||
| Eventide Asset Management | |||
| Verition Fund Management | |||
| Symbiosis Group | |||
| Total Funding | $778m |
Business Model:
There is no data of it.
Services Offered thru Biosplice Therapeutics:
By focusing on the CLK/DYRK family of kinases, Biosplice Therapeutics has developed novel biological insights and distinctive chemical compounds that offer therapeutic regulation of alternative splicing. Within the “command and control” hub of proteome diversification, these kinases control the selection of tissue-specific and disease-selective RNA splice-sites, making them druggable targets.
Awards & Recognition:
There is no data of it.
Competitors:
Twist Bioscience, Lycia Therapeutics, and Seismic Therapeutic are prospective substitutes for and rivals of Biosplice Therapeutics.
Latest News:
- New clinical data for Cirtuvivint (Sm08502) were released by Biosplice Therapeutics at a meeting of the European Society for Clinical Oncology.
- Closed $120 million in equity financing for Biosplice Therapeutics to advance its alternative splicing platform.
- Biosplice Therapeutics’ completion of a $120 million equity funding round will enable company to develop its alternative splicing platform.
Future Plans:
There is no data of it.
Some FAQs:
Is Biosplice a publicly traded company?
Since Biosplice Therapeutics is still a private company, it does not yet have a ticker symbol.
What does Biosplice do?
By focusing on the CLK/DYRK family of kinases, Biosplice Therapeutics has developed novel biological insights and distinctive chemical compounds that offer therapeutic regulation of alternative splicing.
Is Esperion Therapeutics a good buy?
The consensus analyst rating for Esperion is “Moderate Buy.” This is based on six Wall Street analysts’ ratings.
What happened to Samumed?
Unexpectedly, Samumed has just changed its name to Biosplice Therapeutics (San Diego). Osman Kibar, the CEO, has retired. Cevdet Samikoglu is the newest CEO.
Where is Biosplice Therapeutics’s headquarters?
Biosplice Therapeutics is located in San Diego, California, United States.
Who invested in Biosplice Therapeutics?
There are 11 investors in Biosplice Therapeutics, including Verition Fund Management and Sands Capital Ventures.
Conclusion:
A new biotechnology investment syndicate has provided $120 million in equity funding to Biosplice Treatments, Inc. (“Biosplice”), a clinical-stage biotechnology firm that is developing novel therapeutics based on alternative pre-mRNA splicing for serious disorders.
Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and other investors participated in this most recent round, which also included previous investor backing. In connection with the funding, the company’s board of directors will welcome Joy Ghosh, PhD, of Eventide Asset Management, and Gur Roshwalb, MD, of aMoon.
Cevdet Samikoglu, CEO of Biosplice, said, “We are thrilled to unify with our new investors and board behind the huge therapeutic potential of Biosplice. “This funding round enables us to hasten the development and commercialization of lorecivivint, our ground-breaking Phase 3 osteoarthritis programme.
We also anticipate realising the enormous potential of our oncology programme, as well as that of neurology and other crucially underserved areas.
